ECLIPSE (Evolution of Cancer, Leukemia and Immunity Project) is a novel organization within the MD Anderson Cancer Center, Houston, Texas, with the mission of making MDACC and its partners recognized leaders in the identification and development of innovative immunooncology therapies that will cure all hematologic malignancies.
The primary requirement for an individual in this position is an experienced and highly motivated individual with hands-on experience in identification and validation of potential therapeutic targets for patients with advanced hematological malignancies. Such data generated from the team is expected to influence a broad array of decisions around target prioritization and generation of therapeutic modalities against those particular targets. The successful candidate will participate in cross-functional research to design and develop novel assays that will support an understanding of target biology. The selected candidate will be expected to work at the bench and contribute to development and implementation of potential biomarker strategies to support clinical development. Previous experience in biotech/pharma is highly preferred.
Salary range: Min $98,000 - Mid $122,500 - Max $147,000
The mission of The University of Texas M. D. Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.